Scientists Find a Key Protein That Helps Cancer Cells Grow

Scientists have discovered that a protein called ROR1 plays a big role in helping a type of blood cancer called mantle cell lymphoma, or MCL, grow and survive. MCL is a rare but serious cancer that affects white blood cells. Researchers studied how ROR1 works inside cancer cells and what happens when it is removed. Their findings could one day help doctors develop better treatments for people with this disease.

The research team looked at MCL cancer cells grown in the lab and also at tissue samples taken from real patients. They found that ROR1 shows up on the surface of MCL cancer cells and becomes even more active when the cells are under stress. This was an important clue, because it suggested that cancer cells might use ROR1 as a kind of backup system to keep growing even when other signals fail.

One of the most striking findings was that ROR1 can take over the job of a normal cell signal called BCR signaling. BCR signaling usually tells healthy white blood cells when to grow and when to stop. In MCL cancer cells, this signal is already overactive, but ROR1 seems to be able to do the same job on its own. When scientists blocked ROR1, the cancer cells slowed down and began to die.

To understand how ROR1 affects cancer cells so deeply, researchers used powerful lab tools to study three different things at once. They looked at how genes were being turned on or off across the whole cell, studied the cell's metabolome, and examined the phosphoproteome, which shows which proteins are being switched on or off. All three studies showed that ROR1 has wide and far-reaching effects on how cancer cells behave.

The team also tested their findings in living mice. They placed human MCL cancer cells into mice and tracked the tumors using a special kind of light called bioluminescence. Mice whose cancer cells had ROR1 blocked showed much less tumor growth than mice with normal cancer cells. This confirmed that ROR1 really does matter for cancer growth inside a living body.

Researchers used a modern gene-editing tool called CRISPR to remove ROR1 from cancer cells. When ROR1 was gone, the cancer cells could not grow as well and were more likely to die. The team also found that ROR1 affects how cancer cells use energy — cells with ROR1 were better at using glucose, a type of sugar, to fuel their fast growth.

The scientists believe that ROR1 works through several different pathways at the same time, which makes it a strong target for new cancer drugs. Because ROR1 appears mainly on cancer cells and not on most healthy adult cells, a drug targeting ROR1 might attack the cancer without harming healthy tissue. Researchers hope these findings will lead to better, safer treatments for MCL patients in the future.